TiffanyATrainaMD

Clinical Trials

• Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model Start of enrollment: 2005 Jun 01

  Completed

  Phase 1, Phase 2

• Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23

  Completed

  Phase 2

• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Start of enrollment: 2007 Oct 01

  Completed

  Phase 2

• Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer Start of enrollment: 2008 Jul 01

  Completed

  Phase 2

• GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy Start of enrollment: 2010 Nov 01

  Terminated

• Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer Start of enrollment: 2011 Mar 01

  Completed

  Phase 2

• Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer Start of enrollment: 2011 Mar 03

  Completed

  Phase 2

• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01

  Completed

  Phase 2

• Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2013 Aug 01

  Unknown status

  Not Applicable

• Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01

  Terminated

  Phase 1, Phase 2

• Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer Start of enrollment: 2015 Jul 01

  Active, not recruiting

  Not Applicable

• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Start of enrollment: 2015 Aug 01

  Completed

  Phase 1, Phase 2

• Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Start of enrollment: 2015 Nov 11

  Active, not recruiting

  Phase 1, Phase 2

• Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Start of enrollment: 2016 May 19

  Active, not recruiting

  Phase 2

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02

  Terminated

  Phase 2

• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer Start of enrollment: 2023 Oct 18

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all